title: Reply to M. Voskoboynik et al.
authors: Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY hymand@mskcc.org.
authors: David M
authors: DM
authors: Hyman
authors: Memorial Sloan Kettering Cancer Center, New York, NY.
authors: Anne A
authors: AA
authors: Eaton
authors: Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY.
authors: Mrinal M
authors: MM
authors: Gounder
authors: The National Cancer Institute, Bethesda, MD.
authors: S Percy
authors: SP
authors: Ivy
authors: Memorial Sloan Kettering Cancer Center, New York, NY.
authors: Alexia
authors: A
authors: Iasonos
authors: Memorial Sloan Kettering Cancer Center, New York, NY.
authors: David R
authors: DR
authors: Spriggs
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D017321:Clinical Trials, Phase I as Topic / Q000379:methods*; D006801:Humans; D049451:Nomograms
chemical_list: D000970:Antineoplastic Agents